News

Canadian Tire Reports Loss in Q3

1 Mins read

Canadian Tire, a leading retail company, reported a loss of 27.8 million Canadian dollars ($20.2 million) in the third quarter. This was attributed to a charge related to the acquisition of its financial service arm stake. In contrast, the company had reported a profit of C$225 million in the same quarter last year.

The loss was primarily due to a change in fair value charge of C$328 million resulting from the acquisition of Bank of Nova Scotia’s 20% stake in Canadian Tire Financial Services in late October. The company’s normalized earnings were C$2.96 per share, falling short of analysts’ expectations of C$3.29 per share.

Despite the loss, Canadian Tire saw a slight increase in revenue, which rose to C$4.25 billion from C$4.23 billion. This exceeded analyst expectations of a decline to C$4.18 billion. However, the company noted that consumer demand has been softening, leading to a 1.6% decrease in consolidated comparable sales.

In October, Canadian Tire regained full ownership of its financial-services arm by acquiring the stake from a Canadian bank for C$895 million. This move is expected to provide the company with greater flexibility in delivering value to its 11 million active loyalty members, including 2.3 million credit-card holders.

Related posts
News

GitLab Stock Surges on First Ever Adjusted Operating Profit

1 Mins read
GitLab’s stock experienced a significant surge on Tuesday following the announcement of its first ever adjusted operating profit. Despite this positive development,…
News

Virgin Galactic Faces Stock Decline Amid Founder's Money Decision

2 Mins read
Virgin Galactic stock experienced a sharp decline in early trading on Monday due to founder Richard Branson’s announcement that he won’t be…
News

EyePoint Pharmaceuticals Announces Positive Results in Phase 2 Trial for Macular Degeneration Treatment

1 Mins read
EyePoint Pharmaceuticals, a Massachusetts-based company, revealed exciting news on Monday regarding the second-phase trial of its investigational treatment for macular degeneration. The…

Leave a Reply

Your email address will not be published. Required fields are marked *

72 + = 78